Bausch & Lomb Initiated with 'buy'

Analysts at First Albany initiate coverage of Bausch & Lomb (BOL) with a "buy" rating. The target price is set to $42. The analysts mention that Bausch & Lomb has developed into a market leader with one of the broadest product ranges in the ophthalmic industry. The new CEO, Ron Zarella, seems to have introduced an effective business, reflected in the consistently above-average performance of the company in the last six quarters, the analysts observe. First Albany indicates that a significant new development is the introduction of products with high-growth/high-margin potential.The analysts mention that Bausch & Lomb has developed into a market leader with one of the broadest product ranges in the ophthalmic industry. The new CEO, Ron Zarella, seems to have introduced an effective business, reflected in the consistently above-average performance of the company in the last six quarters, the analysts observe. First Albany indicates that a significant new development is the introduction of products with high-growth/high-margin potential.